Janssen Pharmaceutica NV, a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), immunology and inflammation (rheumatoid arthritis, psoriasis and inflammatory bowel diseases), mental health (MDD, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health. In Europe, the main research facilities for Janssen Research & Development are located in Beerse, Belgium, with research focused around the therapeutic areas of neuroscience, oncology, infectious diseases and immunology. With over 50 years of experience in pharmaceutical R&D, Janssen enjoys an international reputation for pharmaceutical innovation and quality.

Globally, Janssen has been part of 71 IMI projects (37 IMI1, 44 IMI2) of which 18 as a Project Leader.


Sign up to stay informed

    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu